Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

MK-0893

Generic Name: MK-0893

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₂₇Cl_₂N_₃O_₄

Unique Ingredient Identifier: CCP2U6LWTP

Overview

MK0893 has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.

Background

MK0893 has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)

Phase 1

Completed

Posted: 2013/12/16

Sponsor:Merck Sharp & Dohme ...

ID:NCT02012166

A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

Phase 2

Completed

Posted: 2013/12/09

Sponsor:Merck Sharp & Dohme ...

ID:NCT02004886

A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)

Phase 1

Completed

Posted: 2009/05/15

Sponsor:Merck Sharp & Dohme ...

ID:NCT00902161

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

Phase 2

Completed

Posted: 2008/03/07

Sponsor:Merck Sharp & Dohme ...

ID:NCT00631488

Dose-Range Finding Study for MK0893 (0893-008)

Phase 2

Terminated

Posted: 2007/05/28

Sponsor:Merck Sharp & Dohme ...

ID:NCT00479466

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy